JNJJohnson & Johnson
$261.45+53% 1Y
$261.45
$171.2152 weeks$278.28
The financials
Johnson & Johnson by the numbers
Johnson & Johnson (JNJ) reported revenue of $25.3B in Q2 2026 (quarter ended Jun 28, 2026), up 6.6% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $5.53B (22% of revenue). For the full year FY2025, revenue was $94.2B (+6.0% year on year) and net income $26.8B. Its largest product in Q2 2026 was DARZALEX at $2.44B, 19% of the disclosed total, ahead of Tremfya at 11%. The next results filing is expected around Oct 13, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $25.3B | $23.7B | +6.6% |
| Gross profit | $17.3B | $16.1B | +7.1% |
| Net income | $5.53B | $5.54B | −0.1% |
| Diluted EPS | $2.27 | $2.29 | −0.9% |
| Product | Revenue | Share |
|---|---|---|
| DARZALEX | $2.44B | 19% |
| Tremfya | $1.47B | 11% |
| INVEGASUSTENNAXEPLIONTRINZATREVICTA | $738M | 5.7% |
| Xarelto | $664M | 5.1% |
| GENERAL | $596M | 4.6% |
| TRAUMA | $536M | 4.1% |
| SPRAVATO | $514M | 4.0% |
| ADVANCED | $499M | 3.8% |
| CARVYKTI | $472M | 3.6% |
| CONTACTLENSESOTHER | $445M | 3.4% |
| SPINEOTHER | $423M | 3.3% |
| OPSUMITOPSYNVI | $416M | 3.2% |
| ERLEADA | $396M | 3.0% |
| UPTRAVI | $386M | 3.0% |
| CAPLYTA | $361M | 2.8% |
| Stelara | $336M | 2.6% |
| PREZISTAPREZCOBIXREZOLSTASYMTUZA | $296M | 2.3% |
| HIPS | $283M | 2.2% |
| Simponi Simponi Aria | $260M | 2.0% |
| KNEES | $228M | 1.8% |
| Remicade | $215M | 1.7% |
| RYBREVANTLAZCLUZE | $190M | 1.5% |
| Tecvayli | $186M | 1.4% |
| IMBRUVICA | $149M | 1.1% |
| Other Oncology | $131M | 1.0% |
| SURGICAL | $120M | 0.9% |
| TALVEY | $112M | 0.9% |
| Other Immunology | $85M | 0.7% |
| OTHERNEUROSCIENCE | $34M | 0.3% |
| Other | $13M | 0.1% |
| CONCERTA Methylphenidate | $12M | 0.1% |
| EDURAN Trilpivirine | $3.0M | 0.0% |
| Other Infectious Diseases | $1.0M | 0.0% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $13.00B (+10.0%)
Other Immunology grew +963% year on yearStelara -69% year on year
Segment Latestquarter on quarteryear on year
- DARZALEX$2.44B$2.44Bquarter on quarter +10%year on year +21%+10%+21%
- Tremfya$1.47B$1.47Bquarter on quarter +41%year on year +84%+41%+84%
- INVEGASUSTENNAXEPLIONTRINZATREVICTA$738.0M$738.0Mquarter on quarter -2.6%year on year +0.82%-2.6%+0.82%
- Xarelto$664.0M$664.0Mquarter on quarter +3.4%year on year +6.9%+3.4%+6.9%
- GENERAL$596.0M$596.0Mquarter on quarter +4.7%year on year +5.1%+4.7%+5.1%
- TRAUMA$536.0M$536.0Mquarter on quarter +0.75%year on year +7.0%+0.75%+7.0%
- SPRAVATO$514.0M$514.0Mquarter on quarter +27%year on year +40%+27%+40%
- ADVANCED$499.0M$499.0Mquarter on quarter +4.6%year on year +4.6%+4.6%+4.6%
- CARVYKTI$472.0M$472.0Mquarter on quarter +9.0%year on year +32%+9.0%+32%
- CONTACTLENSESOTHER$445.0M$445.0Mquarter on quarter -4.9%year on year +3.7%-4.9%+3.7%
- SPINEOTHER$423.0M$423.0Mquarter on quarter +9.3%year on year +0.24%+9.3%+0.24%
- OPSUMITOPSYNVI$416.0M$416.0Mquarter on quarter -3.9%year on year +3.2%-3.9%+3.2%
- ERLEADA$396.0M$396.0Mquarter on quarter +16%year on year +4.8%+16%+4.8%
- UPTRAVI$386.0M$386.0Mquarter on quarter +0.26%year on year +1.0%+0.26%+1.0%
- CAPLYTA$361.0M$361.0Mquarter on quarter +34%year on year +71%+34%+71%
- Stelara$336.0M$336.0Mquarter on quarter +53%year on year -69%+53%-69%
- PREZISTAPREZCOBIXREZOLSTASYMTUZA$296.0M$296.0Mquarter on quarter -11%year on year -5.1%-11%-5.1%
- HIPS$283.0M$283.0Mquarter on quarter +2.2%year on year +4.4%+2.2%+4.4%
- Simponi Simponi Aria$260.0M$260.0Mquarter on quarter -3.3%year on year -15%-3.3%-15%
- KNEES$228.0M$228.0Mquarter on quarter -4.6%year on year +0.88%-4.6%+0.88%
- Remicade$215.0M$215.0Mquarter on quarter -20%year on year -24%-20%-24%
- RYBREVANTLAZCLUZE$190.0M$190.0Mquarter on quarter +8.6%year on year +37%+8.6%+37%
- Tecvayli$186.0M$186.0Mquarter on quarter +46%year on year +63%+46%+63%
- IMBRUVICA$149.0M$149.0Mquarter on quarter +4.2%year on year -38%+4.2%-38%
- Other Oncology$131.0M$131.0Mquarter on quarter +54%year on year +134%+54%+134%
- SURGICAL$120.0M$120.0Mquarter on quarter +8.1%year on year -6.3%+8.1%-6.3%
- TALVEY$112.0M$112.0Mquarter on quarter +11%year on year +37%+11%+37%
- Other Immunology$85.0M$85.0Mquarter on quarter +124%year on year +963%+124%+963%
- OTHERNEUROSCIENCE$34.0M$34.0Mquarter on quarter -11%year on year -24%-11%-24%
- Other$13.0M$13.0Mquarter on quarter +8.3%year on year -19%+8.3%-19%
- CONCERTA Methylphenidate$12.0M$12.0Mquarter on quarter -45%year on year -50%-45%-50%
- EDURAN Trilpivirine$3.0M$3.0Mquarter on quarter -57%year on year -50%-57%-50%
- Other Infectious Diseases$1.0M$1.0Mquarter on quarter 0.00%year on year -50%0.00%-50%
Drug Manufacturers, General
The closest names by size in the same industry